Atlas Trials

Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

Clinical trial NCT03499873 · COMPLETED

Trial details

NCT number
NCT03499873
Sponsor
Actavis Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Cataract
Start date
2018-03-28
Primary completion
2018-10-31
Enrollment
448

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.